Treasury expected to tighten scrutiny of China biotech deals

· Health · United States · China

The pharmaceutical industry is bracing for a stricter assessment of China deals from the US Treasury Department, despite months of work aimed at escaping a harsh clampdown on buying new assets there, Endpoints News reported after speaking with people familiar with the matter. The expected shift concerns cross-border transactions in which pharma companies acquire or license Chinese biotech assets. The report did not specify the measures Treasury might adopt. The development comes as Western drugmakers have increasingly turned to China for pipelines, making the regulatory stance of the US government a key variable for dealmaking.

Why it matters：US regulatory scrutiny of China biotech licensing and acquisitions could reshape cross-border deal flow that has become a major source of pipelines for global drugmakers.

Key points

  • The report is based on Endpoints' conversations with people familiar with the matter.
  • The focus is on deals to buy or license Chinese biotech assets.
  • Specific measures Treasury might take were not disclosed.

Sources (original reporting)

More stories from this day